Who are Havrix 720 Junior's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Healive® Lot 3, Hepatitis A vaccine, Vaqta Injectable Product, Hepatitis A Virus, Hepatitis A (control), HAV vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/havrix-720-junior.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Havrix 720 Junior — Competitive Intelligence Brief

Havrix 720 Junior (Havrix 720 Junior) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated viral vaccine Hepatitis A virus surface antigen Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Havrix 720 Junior (Havrix 720 Junior) — Chiang Mai University. Havrix 720 Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Havrix 720 Junior TARGET	Havrix 720 Junior	Chiang Mai University	marketed	Inactivated viral vaccine	Hepatitis A virus surface antigen
Healive® Lot 3	Healive® Lot 3	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Hepatitis A virus surface antigens
Hepatitis A vaccine	Hepatitis A vaccine	MacroGenics	marketed	inactivated viral vaccine	Hepatitis A virus surface antigens
Vaqta Injectable Product	Vaqta Injectable Product	National Taiwan University Hospital	marketed	Inactivated viral vaccine	Hepatitis A virus surface antigen
Hepatitis A Virus	Hepatitis A Virus	Novartis	marketed	Inactivated viral vaccine	Hepatitis A Virus surface antigens
Hepatitis A (control)	Hepatitis A (control)	International Vaccine Institute	marketed	inactivated viral vaccine	Hepatitis A virus surface antigens
HAV vaccine	HAV vaccine	International Agency for Research on Cancer	phase 3	Inactivated viral vaccine	Hepatitis A virus surface antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 9 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
GlaxoSmithKline · 5 drugs in this class
Valneva Austria GmbH · 4 drugs in this class
Medical University of Vienna · 3 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Havrix 720 Junior — Competitive Intelligence Brief. https://druglandscape.com/ci/havrix-720-junior. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab